Respiratory Syncytial Virus (RSV) Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Respiratory Syncytial Virus (RSV) Market is Segmented By Drug Type (Ribavirin, Nirsevimab, Virazole, Palivizumab, Riba Tab, Others), By Dosage Form (Oral, Injectable, Inhaler, Others), By Treatment Type (Immune prophylaxis, Supportive care, Antiviral Medications), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and By Region (North America, Europe, South America, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Respiratory Syncytial Virus (RSV) Market Size

The Global Respiratory Syncytial Virus (RSV) market reached USD 1.2 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 2.4 billion by 2030. The market is expected to exhibit a CAGR of 10.2% during the forecast period (2024-2031). One of the primary factors fueling the growth of this market is the growing elderly population.

Other key factors driving the growth of the Respiratory Syncytial Virus (RSV) therapeutics market include the rising incidence of RSV infections in infants and young children, the availability of better treatment options, and the presence of a large number of hospitals and specialty clinics.

According to WHO, by 2030, one in every six persons on the planet will be 60 or older. At this point, the proportion of the population aged 60 and up will rise from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of adults aged 60 and up will have doubled. As a result, the growing elderly population will provide an opportunity for the respiratory syncytial virus therapeutics market to grow.

Respiratory Syncytial Virus (RSV) Market Scope

For more Biotechnology related reports, please click here 

Respiratory Syncytial Virus (RSV) Market Dynamics

Increasing Prevalence of RSV is a Key Factor Helping Market Expansion

RSV is a common respiratory virus that usually affects young children and can cause mild to severe respiratory disease. RSV infections are most common in the autumn, winter, and early spring. RSV is a leading cause of lower respiratory tract infections in newborns and young children, including bronchiolitis and pneumonia. It can also affect older people and people with compromised immune systems.

For instance, according to NIAID, RSV is the leading cause of bronchiolitis (inflammation of the tiny airways in the lungs) among infants under one year old in the United States, accounting for roughly 58,000 hospitalisations each year. RSV infection is expected to kill approximately 14,000 persons over the age of 65 in the United States each year. RSV affects an estimated 64 million people worldwide and kills 160,000 people each year. These are the specific aspects that drive market expansion.

Rise in the Clinical Trials by the Key Players is Expected to Drive the Market Growth

The increase in clinical trials by key companies is projected to fuel market growth. For instance, on May 12, 2023, in a real-world clinical trial setting, the Nirsevimab medication developed by Sanofi and AstraZeneca reduced RSV baby hospitalizations by 83%. As a result, new findings from the HARMONIE Phase 3b clinical trial reveal that a single dose of nirsevimab reduced hospitalizations due to RSV-related LRTD by 83.21% (95% CI 67.77 to 92.04; P0.001) in children under 12 months of age compared to infants who received no RSV intervention. 

Additionally, on November 01, 2022, Pfizer announced positive top-line data from the MATISSE (MATernal Immunisation Study for Safety and Efficacy) Phase 3 clinical trial (NCT04424316) investigating its bivalent RSV prefusion vaccine candidate, RSVpreF or PF-06928316, when administered to pregnant participants to help protect their infants from RSV disease after birth. 

High Cost of Disease Management will Hamper the Market Growth

The cost of managing RSV is considerable, which is projected to hinder market expansion. The average cost of palivizumab each dose, for example, ranged from $1,660 for infants under 6 months of age to $2,500 for children in their second year of life. Immunoprophylaxis with palivizumab cost roughly $302,000 to prevent one RSV-related hospitalization in preterm infants fewer than 6 months of age without additional reasons. This aspect may impede the worldwide RSV market's expansion even further.

Respiratory Syncytial Virus (RSV) Market Segment Analysis

The Global Respiratory Syncytial Virus (RSV) market is segmented drug type, dosage form, treatment type, distribution channel, and region.

The Nirsevimab Segment is Expected to Hold a Dominant Position in the Market Over The Forecast Period

Nirsevimab accounted for the biggest market stake accounting for approximately 31.20% of the Respiratory Syncytial Virus (RSV) market in 2022. Nirsevimab, a monoclonal antibody that targets respiratory syncytial virus, prevented term and late-preterm newborns from RSV-related hospitalization and severe lower respiratory tract illness. Nirsevimab is an antibody that has been created to provide direct RSV protection to neonates and infants in order to assist avoid LRTI caused by RSV. Monoclonal antibodies do not require immune system activation to provide quick, rapid, and direct protection against illness. Product approvals by organisations and the number of clinical trials are projected to dominate the segment. For instance, The European Commission approved nirsevimab in October 2022, while the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved it in November 2022.

Additionally, on January 05, 2023, The US Food and Drug Administration (FDA) has accepted AstraZeneca's Biologics Licence Application (BLA) for nirsevimab for review for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants entering or during their first RSV season, and for children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season. And it is these things that will fuel segment expansion.

Source: DataM Intelligence Analysis (2023)

Respiratory Syncytial Virus (RSV) Market Geographical Share

North America Holds a Dominant Position in the Global Respiratory Syncytial Virus (RSV) Market

North America is estimated to hold about 39.4% of the total market share throughout the forecast period. The growing burden of respiratory syncytial virus infections in the region, growing research and development activities, increasing investments, and supporting government initiatives and key initiatives taken by key market players are the primary driving factors for the growth of the respiratory syncytial virus (RSV) therapeutics market.

According to the article "Increased Interseasonal Respiratory Syncytial Virus (RSV) Activity in Parts of the Southern United States," published by the Centres for Disease Control and Prevention in June 2021, RSV causes approximately 60,000 hospitalisations with 100-500 deaths among children younger than 5 years old and 175,000 hospitalisations with 15,000 deaths among adults 65 years or older in the United States each year. As a result, the country's RSV infection load is rising, raising demand for diagnostics and driving the market. 

Source: DataM Intelligence Analysis (2023)

Respiratory Syncytial Virus (RSV) Market Companies

The major global players in the market include Sanofi, GSK plc, Pfizer, AstraZeneca, AbbVie, Bausch Health Companies, Bavarian Nordic, Merck & Co, Moderna, Inc., and mAbxience, among others.

COVID-19 Impact on Respiratory Syncytial Virus (RSV) Market

Russia-Ukraine War Impact Analysis

The Russia-Ukraine is estimated to have a minimal impact on the global respiratory syncytial virus market owing to the low prevalence and absence of key market players in this region. However, the impact of the import and export of raw materials, test types, and devices is anticipated to have little influence over the global respiratory syncytial virus market in the forecast period.

Artificial Intelligence Impact Analysis

Artificial intelligence is anticipated to impact positively. To aid in the detection and diagnosis of RSV-related lung abnormalities, AI algorithms have been created to analyse medical imaging data such as chest X-rays or computed tomography (CT) scans. 

These algorithms can help healthcare workers by giving accurate and timely interpretations, which could lead to earlier diagnosis and intervention. AI has the potential to improve RSV research, diagnosis, treatment, and prevention measures, while also providing vital assistance to healthcare professionals and researchers working in this field.

By Drug Type 

• Ribavirin
• Nirsevimab
• Virazole
• Palivizumab
• Riba Tab
• Others

By Dosage Form 

• Oral
• Injectable
• Inhaler
• Others

By Treatment Type 

• Immune prophylaxis
• Supportive care
• Antiviral Medications

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • The U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Key Developments

• On May 03, 2023, GSK plc announced that Arexvy (respiratory syncytial virus vaccine, adjuvanted) has been approved by the US Food and Drug Administration (FDA) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in people aged 60 and up. This is the world's first RSV vaccination for older individuals to be licensed.
• On November 4, 2022, Sanofi (SASY.PA) and AstraZeneca's Beyfortus were authorized by the European Commission for the prevention of a common and highly contagious kind of respiratory illness in newborns. The long-acting medication, also known as nirsevimab, was granted EU marketing authorization for the prevention of sickness caused by respiratory syncytial virus (RSV) infections.

Why Purchase the Report?

• To visualize the global respiratory syncytial virus market segmentation based on drug type, treatment type, dosage form, distribution channel, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of respiratory syncytial virus market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Type mapping available as Excel consisting of key types of all the major players.

The global respiratory syncytial virus market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies